Article by Lift News
The Hydropothecary Corporation announced today that it is recalling fourteen products due to detection of myclobutanil, an unauthorized pesticide product. The company has also resumed selling cannabis products from certain lots after completion of additional testing following the Company’s previously announced voluntary stop-sale on its products.
The Quebec company says lot retesting was carried out to ensure there was no presence of myclobutanil, a pesticide approved for use in agriculture (e.g. apples trees, almonds, strawberries, vegetables, soybeans and grape vines), but not for use on cannabis. Results of the lots now released for sale show no sign of contamination. Health Canada has been provided with these test results.
The fourteen recalled lots, however, tested positive for trace amounts over 0.01 parts per million (ppm), but no more than 0.08 parts per million. Health Canada has recently announced that they will be requiring pesticide testing for all cannabis producers, reportedly to levels of .01 ppm. As myclobutanil is an unauthorized pesticide, there are no known acceptable limits on cannabis in Canada. A limit of .01 ppm is based on current accuracy of available technology. You can find past updates on cannabis recalls here.
Hydropothecary says they will continue to test product using thier previously implemented voluntary testing program, and they are supportive of Health Canada’s mandatory testing initiative announced on May 5, 2017. With the resumed selling, the company currently has 13 of 14 products available for sale.
“Hydropothecary has always put our customers’ health and safety first, through providing well grown and rigorously tested medical cannabis of the highest quality. Today’s announcement that we have lifted the voluntary stop-sale is a direct result of our quality assurance efforts. We will continue to strive for the highest possible standards for all of our products and to put patients first,” said Sebastien St-Louis, co-founder and CEO, in a company press release.
Based on the completion of other additional screening, the Company is currently voluntarily recalling fourteen lots of medical cannabis, which were supplied between February 1, 2016 and May 1, 2017, due to the detection of myclobutanil. These products have tested positive for trace amounts over 0.01 parts per million, but no more than 0.08 parts per million. The recalled lots are lots numbered 45, 46, 47, 54, 58, 59, 102, 109, 123, 127, 128, 129, 148 and 150.